Interpace Biosciences (IDXG) Tops Q1 EPS by 29c

Interpace Biosciences (OTC: IDXG) reported Q1 EPS of $0.10, $0.29 better than the analyst estimate of ($0.19). Revenue for the quarter came in at $9.8 million versus the consensus estimate of $12 million.

For earnings history and earnings-related data on Interpace Biosciences (IDXG) click here.

You May Also Be Interested In

• Key things to know ahead of SK Hynix’s blockbuster US listing
• Simulations Plus (SLP) Tops Q3 EPS by 7c
• Hongli Group receives Nasdaq minimum bid price deficiency notice